Subscribe

Subscribe

Latest Content

Solar

Storage

Wind

Event Spotlight

BLOGS

DISTRIBUTECH+ RECAP: Energy Storage Utility Case Studies

Webcast

OPINION

RESOURCES

CLARION ENERGY MEDIA

POWER & ENERGY EVENT SERIES

Privacy Policy

Copyright © 2019 - 2021

Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neurocrine Bioscienc (NQ: NBIX )

111.88 -2.07 (-1.82%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,323,892
Open 113.66
Bid (Size) 111.00 (1)
Ask (Size) 115.65 (1)
Prev. Close 113.95
Today's Range 110.95 - 114.05
52wk Range 103.63 - 157.98
Shares Outstanding 100,900,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
"Rule Breaker Investing" Market Cap Game Show: Throwdowns & Long-Term Wins
Motley Fool analysts Matt Argersinger and Yasser El-Shimy face off. 
Via The Motley Fool
Despite its growth, NASDAQ:NBIX remains within the realm of affordability.
In the world of growth stocks, NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) shines as a value proposition. 
Via Chartmill

Performance

YTD
-15.07%
-15.07%
1 Month
-10.57%
-10.57%
3 Month
-19.56%
-19.56%
6 Month
-18.70%
-18.70%
1 Year
+1.08%
+1.08%

More News

Read More
For those who appreciate value investing, NASDAQ:NBIX is a compelling option with its solid fundamentals.
Via Chartmill
NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move.
Via Chartmill
Neurocrine Shifts Focus To New Schizophrenia Treatment After Luvadaxistat Trial Misses Endpoint
Via Benzinga
Decoding 19 Analyst Evaluations For Neurocrine Biosciences
Via Benzinga
NASDAQ:NBIX, a growth stock which is not overvalued.
Via Chartmill
Evaluating Neurocrine Biosciences: Insights From 15 Financial Analysts
Via Benzinga
Intel, Moderna And Dollar General Were Among Top 10 Large Cap Losers In August: Are The Others In Your Portfolio?
Via Benzinga
Don't overlook NASDAQ:NBIX—it's a hidden gem with strong fundamentals and an attractive price tag.
Via Chartmill
Dollar General, Temu Parent PDD And Super Micro Computer Are Among Top 10 Large Cap Losers Last Week (Aug 25-Aug 31): Are The Others In Your Portfolio?
Via Benzinga
Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move.
Via Chartmill
Why Neurocrine Biosciences Stock Was Tumbling This Week
Via The Motley Fool
Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock
Via Benzinga
NVIDIA To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Nasdaq Down Over 1%; Foot Locker Shares Tumble After Q2 Results
Via Benzinga
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
Via Benzinga
NASDAQ:NBIX is not too expensive for the growth it is showing.
Via Chartmill
US Stocks Mixed; JM Smucker Slashes Annual Guidance
Via Benzinga
Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers
Via Investor's Business Daily
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
Via Benzinga
Why the quality investor may take a look at NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX).
Via Chartmill
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
New Study Reveals How Classical Music Could Revolutionize Depression Care
Via PressReach
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.